Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of topical diacerein 1% ointment for epidermolysis bullosa simplex
MOH_2017-05-21_000407Phase 2Not yet recruiting
- Sponsor
- Castle Creek Biosciences
- Start
- Apr 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diacerein in epidermolysis bullosa simplex (EBS) (2 arms), sponsored by Castle Creek Biosciences. Planned start Apr 2017; status: not yet recruiting.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on MOH_2017-05-21_000407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-21_000407.